In late January, Dr Anban Pillay, Deputy Director-General in South Africa’s National Department of Health, revealed that South Africa would pay more than double the price paid by the European Union (EU) for AstraZeneca’s COVID-19 vaccine. This set off a flurry of questions on how vaccine prices are set and why, in many cases, the prices themselves are not known to the public. Catherine Tomlinson takes a closer look at the issues involved.
Before any COVID-19 vaccines can be made available in South Africa, they must be authorised by South Africa’s medicines regulator—the South African Health Products Regulatory Authority (SAHPRA). Catherine Tomlinson explores how SAHPRA is preparing to review and authorise the use of COVID-19 vaccines in the country and the different authorisation approaches they may use.
South Africa does not currently register medical devices. So what does it mean when the regulator announces that a new COVID-19 test or ventilator has been authorised? Catherine Tomlinson unpacks what is required to market a medical device in South Africa.
Having pressed the imperative of equitable global sharing of COVID-19 health products, President Ramaphosa must now declare support for the Intellectual Property Pool for COVID-19, argues Professor Yousuf Vawda & Professor Brook K Baker.
As the confirmed number of COVID-19 infections in South Africa climbs toward 20 000, a group of 80 leading academics, teachers and researchers have written to President Cyril Ramaphosa to urge reform of South Africa’s Patents Act. We republish the letter in full.
Four provinces have made positive moves to announce that patients on chronic medicines will be able to have their scripts filled for as long as three or four months in order to minimise their exposure to possible COVID-19 infection in public spaces like clinics.